發(fā)布時(shí)間：2018-04-22 10:17

  本文選題：TRIPS協(xié)議 + 彈性條款��； 參考：《中國(guó)新藥雜志》2017年09期

【摘要】：在全球衛(wèi)生治理中,如何平衡藥品研發(fā)技術(shù)創(chuàng)新與藥品可及性之間的問(wèn)題由來(lái)已久,發(fā)達(dá)國(guó)家和發(fā)展中國(guó)家在這一議題上的利益界定與談判策略分歧也逐漸加大。本文通過(guò)分析彈性條款以及發(fā)達(dá)國(guó)家與發(fā)展中國(guó)家持有不同立場(chǎng),認(rèn)為中國(guó)在參與全球衛(wèi)生治理中,充分使用《與貿(mào)易相關(guān)的知識(shí)產(chǎn)權(quán)協(xié)定》(TRIPS協(xié)議)下的彈性條款,維護(hù)發(fā)展中國(guó)家的利益,是必要的選擇。
[Abstract]:In global health governance, the problem of how to balance the technological innovation of drug research and development and the availability of drugs has a long history, and the differences of interest definition and negotiation strategies between developed and developing countries on this issue have gradually increased. Based on the analysis of flexible clauses and the differences between developed countries and developing countries, this paper holds that China makes full use of the flexible clauses under trips in its participation in global health governance. Safeguarding the interests of developing countries is a necessary choice.
【作者單位】： 北京大學(xué)醫(yī)學(xué)人文研究院;北京大學(xué)公共衛(wèi)生學(xué)院全球衛(wèi)生系;
【分類(lèi)號(hào)】：D997.1
，

本文編號(hào)：1786776